Wound healing in diabetic patients is slower than in healthy individuals. Erythropoietin (EPO) has nonhemopoietic targets in the skin, and systemically administered EPO promotes wound healing in experimental animals. This study investigated the effect of topical EPO treatment on defective wound repair in the skin of diabetic rats. Full-thickness excisional skin wounds were made in 38 rats, of which 30 had diabetes. The wounds were then treated topically with a cream that contained either vehicle, 600 IU ml À1 EPO (low dose), or 3,000 IU ml À1 (high dose) EPO. We assessed the rate of wound closure during the 12-day treatment period, and microvascular density (MVD), vascular endothelial growth factor (VEGF), and hydroxyproline (HP) contents, and the extent of apoptosis in wound tissues at the end of the 12-day treatment period. Topical EPO treatment significantly reduced the time to final wound closure. This increased rate of closure of the two EPO-treated wounds in diabetic rats was associated with increased MVD, VEGF, and HP contents, and a reduced extent of apoptosis. In light of our finding that topical EPO treatment promotes skin wound repair in diabetic rats, we propose that topical EPO treatment is a therapeutically beneficial method of treating chronic diabetic wounds.
INTRODUCTION
Normal wound healing of damaged skin is a serial process of well recognized and predictable events, in which there are four distinct overlapping phases: hemostasis, inflammation, proliferation, and remodeling (Stadelmann et al., 1998; Quinn, 1998) . Interplay between blood cells, endothelial cells, fibroblasts, and keratinocytes, and the local release of growth factors and cytokines influences the rate of skin wound repair. Any disruption in this interplay delays this process (Clark, 1985; Brown et al., 1992; Shukla et al., 1998) .
In diabetes mellitus, the rate of wound repair is slow (Mustoe, 2004) . The underlying mechanisms of defective wound repair in diabetic patients are not completely understood, but it is thought that all phases of the healing process are disrupted. Indeed, delayed collagen synthesis, impaired epithelialization, and reduced angiogenesis have been described during the proliferative phase of the healing process (Snyder, 2005) . Others have reported that fibroblasts do not produce adequate amounts of extracellular matrix, and the keratinocytes do not re-epithelialize the wound (Mansbridge et al., 1999) . As a result, the skin microvasculature becomes damaged, tissue ischemia ensues, and chronic diabetic wounds develop (Stadelmann et al., 1998; Brem et al., 2000; Sheetz and King, 2002) .
Erythropoietin (EPO) is a glycoprotein hormone that regulates the red blood cell mass by stimulating the proliferation and differentiation of precursor cells, and inhibiting apoptosis in erythroid cells in the bone marrow (Jelkmann, 1994; Ghezzi and Brines, 2004; Brines and Cerami, 2006) . There are also nonhematopoietic cellular targets of EPO in skin, and the existence of EPO receptors has been described on endothelial cells (Anagnostou et al., 1990 (Anagnostou et al., , 1994 , macrophages (Haroon et al., 2003) , fibroblasts, mast cells, and melanocytes, and in hair follicles (Isogai et al., 2006; Bodo et al., 2007) . There is experimental evidence that suggests that EPO has an important function in skin wound healing. Buemi et al. (2002 Buemi et al. ( , 2004 showed that systemically administered recombinant human EPO can stimulate angiogenesis, and promote the healing of random ischemic flaps and ischemic skin wounds in rats. Galeano et al. (2004) reported that systemically administered EPO promoted angiogenesis and the healing of wounds in diabetic mice. These investigators also showed that EPO stimulated angiogenesis and wound healing in experimental burn and incisional wounds in normal mice (Galeano et al., 2006) . Vascular endothelial growth factor (VEGF) is a cytokine that is produced by keratinocytes, macrophages, and fibroblasts (Altavilla et al., 2001) . Owing to the fact that VEGF can exert its effects at all stages in the angiogenetic cascade, and its expression is increased in wound tissue (Galeano and Buemi) , it is considered to be an important mediator of wound healing (Brown et al., 1992) . Accordingly, we hypothesized that applying EPO topically to wounds would be more efficacious than systemically administered EPO in stimulating the release of VEGF from these cutaneous cell types, and in promoting angiogenesis in full-thickness wound repair of diabetic wounds. Using this as a working hypothesis, we initiated a study, the aim of which was to investigate the effect of topical EPO treatment on defective wound repair in an excisional skin wound in a widely used rat model of type 1 diabetes mellitus.
RESULTS
Three rats, two from the vehicle-treated diabetic group and one rat from the high-dose EPO-treated group, died during the treatment period. The elevated blood glucose levels in the diabetic rats were not changed by topical treatment of the wound using either vehicle or EPO-containing creams. Topical treatment of the wound with the vehicle or EPOcontaining creams did not cause any changes in red blood cell, leukocyte, and platelet counts, and in the hemoglobin levels in the non-diabetic and diabetic rats ( Table 1) . The plasma EPO concentration increased significantly only in those rats in which the skin wounds were treated topically for 12 days using the high-dose EPO-containing cream. The EPO concentrations in the wound tissues of diabetic rats that were treated topically for 12 days with either of the EPO-containing creams increased significantly in a dose-dependent manner (Table 1) .
Effect of EPO on rate of wound closure Figure 1 (panel a, b and c right) displays typical healing responses of a skin wound that was treated topically with vehicle-and high-dose EPO-containing creams. The rate of closure of the vehicle-treated wounds of the diabetic rats was slower than that of the vehicle-treated wounds of the nondiabetic rats, and the most significant difference in rate was detected on days 10 and 12. The area of the high-dose EPOtreated open wound was significantly smaller than that of the vehicle-treated wound from day 6 onward. When the areas of the open wound in the low-dose EPO-treated and vehicletreated wounds were compared, a significant difference was detected from day 10 onward. When the areas of the two EPO-treated open wounds were compared, there were significant differences on days 6, 8, 10, and 12 (Figure 2 ).
Effect of EPO on MVD
After 12 days, the microvascular density (MVD) of the vehicletreated wounds of diabetic rats was significantly lower than that of the vehicle-treated wounds of non-diabetic rats. When tissues from the vehicle-treated wounds of diabetic rats were examined histologically, there were avascular areas, ectasic vessels with edema and perivascular hemorrhage, and a marked reduction in capillary ramification. The MVDs in the two EPO-treated wounds were significantly higher than that in the vehicle-treated wounds of diabetic rats (Figure 3c ), and the effect of EPO on MVD was dose dependent. There were well-vascularized areas with an increased expression of CD31, and numerous endothelial islets in the granulation tissue in EPO-treated wounds.
Effect of EPO on wound VEGF and hydroxyproline contents
The VEGF content in the vehicle-treated wounds in diabetic and non-diabetic rats was not statistically different from each other (Figure 4a ). The hydroxyproline (HP) content in vehicletreated wound tissues of diabetic rats was significantly lower than that of non-diabetic rats (Figure 4b ). Topical treatment of the wounds of diabetic rats with EPO-containing creams significantly increased the tissue VEGF and HP contents in a dose-dependent manner.
Effect of EPO on wound apoptosis and apoptotic sensitivity
The extent of apoptosis in the wounds of diabetic rats was greater than that in the wounds of non-diabetic rats, and Hemoglobin levels (g per 100 ml) 15.4 ± 1.6 15.9 ± 1.8 15.1 ± 1.7 15.5 ± 1.9 15.7 ± 1.7 15.8 ± 1.9 16.0 ± 2.0 15.4 ± 1.8 NS Plasma EPO concentration (mU ml À1 ) 18.2 ± 2.0 19.5 ± 2.1 19.1 ± 2.3 18.2 ± 2.2 18.6 ± 2.1 21.6 ± 2.2 18.7 ± 2.0 26.7 ± 2.6 1 o0.05
Conc., concentration; EPO, erythropoietin; N, number of rats; NS not significant; RBC, red blood cells.
1
Indicates difference within the group between day 0 and day 12.
Values are presented as mean ± SD. Statistical significance is set at Po0.05.
topical EPO treatment of the wounds decreased the extent of apoptosis in a dose-dependent manner ( Figure 5a ). The expression of Bax was significantly upregulated, whereas the expression of Bcl-x L was significantly downregulated in the vehicle-treated wounds of diabetic rats when compared with those in the vehicle-treated wounds of non-diabetic rats. (a) One of the two 9-cm 2 full-thickness skin wounds that were made surgically in two representative diabetic rats (left) is displayed. Vehicle-containing cream, and low-dose (600 IU ml
À1
) or high-dose (3,000 IU ml À1 ) erythropoietin (EPO)-containing creams were applied topically to the wounds every second day for 12 days (middle). The wounds were then covered with a dressing film to prevent the cream from being removed and to protect the wound during self-grooming (right). 
Topical Erythropoietin Effects on Defective Wounds
Topical EPO treatment did not inhibit the expression of Bax, irrespective of its concentration. In contrast, Bcl-x L was strongly upregulated in a dose-dependent manner in EPO-treated wounds when compared with the levels in the vehicle-treated wounds of diabetic rats (Figure 5b ). The apoptotic sensitivity of vehicle-treated diabetic wounds was significantly higher than that of vehicle-treated wounds in non-diabetic rats. The apoptotic sensitivities of EPO-treated wounds were significantly lower than that of vehicle-treated wounds of diabetic rats, and the EPO effect was dose dependent (Figure 5c ).
DISCUSSION
The main finding of our study is that topical application of EPO to a full-thickness excisional skin wound in diabetic rats increases the rate of wound repair in a dose-dependent manner. Our data suggest that stimulation of VEGF-induced angiogenesis, increased collagen deposition, and inhibition of apoptosis are the underlying mechanisms of topical EPO action.
In diabetes mellitus, the inability of wounds to heal is associated with an abnormality in one or more phases of the healing process. In our study, we observed that defective wound repair in diabetic rats is associated with reduced wound vascularization and collagen synthesis, and with an increased extent of apoptosis in wound tissues. The area of the open wound after 12 days of topical EPO treatment was substantially smaller than that of wounds that were treated with the vehicle-containing cream. Collagen and VEGF are required for normal wound healing. Therefore, stimulating their synthesis when wound repair is defective would be beneficial for promoting wound healing. We found that the HP and VEGF contents in EPO-treated wounds were higher than those in vehicle-treated wounds in non-diabetic and diabetic rats. Furthermore, these increases were associated with enhanced capillary ramification and vascularization. These results suggest that topically administered EPO exerts its beneficial effects on wound healing by stimulating the deposition of collagen and VEGF secretion.
Increased apoptosis is a common phenomenon in chronic diabetes wounds (Rai et al., 2005) . Farahani and Kloth (2008) claimed that the rate of wound closure is associated with the extent of apoptosis in the wound: an increased rate of wound closure is associated with a reduced extent of apoptosis. We Vehicle-treated non-diabetic Vehicle-treated diabetic Low-dose EPO High-dose EPO Figure 2 . Time course of wound healing in rats. Vehicle-containing cream, and low-dose (600 IU ml À1 ) and high-dose (3,000 IU ml
À1
) erythropoietin (EPO)-containing creams were applied topically to the wounds of non-diabetic and diabetic rats every second day for 12 days. The surface areas of the healing wounds were measured every 2 days and compared by one-way analysis of variance. *Po0.05, **Po0.001-significance of the difference between the mean surface area±SD of the EPO-treated wounds and that of the vehicle-treated wounds in diabetic rats. ) and high-dose (3,000 IU ml À1 ) erythropoietin (EPO)-containing creams were applied topically to the wounds of non-diabetic and diabetic rats every second day for 12 days. Slides were prepared from tissue samples that were harvested on day 12 and microvascular density (MVD) was assessed. .05-significance of the differences between the mean MVD of vehicle-treated wounds in non-diabetic and diabetic rats or the MVD of the low-dose and the high-dose EPO-treated wounds in diabetic rats, respectively.
found that (a) the extent of apoptosis in the wounds of diabetic rats was greater than that in the wounds of nondiabetic rats and (b) topical EPO treatment of the wounds decreased the extent of apoptosis in a dose-dependent manner. We also found that the expression of the antiapoptotic protein, Bcl-x L , was increased and the expression of the pro-apoptotic protein, Bax, was unchanged in EPOtreated wounds. These findings are not surprising because EPO has anti-apoptotic properties (Li et al., 2004) and can inhibit apoptosis by upregulating the expressions of antiapoptotic protein, Bcl-x L , (Wen et al., 2002) . Accordingly, we
propose that topically applied EPO increases the rate of closure of skin wounds in diabetic rats by decreasing the extent of apoptosis and apoptotic sensitivity in wound tissue.
The complete healing of wounds is the result of a complex set of interactions between cellular and acellular components, and the overall clinical experience on the use of growth factors and other mediators to accelerate wound healing in humans and animals has been disappointing. We found that topical application of EPO promotes skin wound repair in diabetic rats. This promotion was not associated with any hematological changes, such as an increase in circulating red blood cells and platelet counts, both of which can act as triggers for the development of numerous adverse effects (Eschbach et al. 1987) . In the light of our finding that topical EPO seems to be both safe and efficacious in promoting wound repair in diabetic rats, we propose that the next stage would be to evaluate its safety and efficacy in diabetic patients.
Our finding that topical EPO treatment promoted wound repair in diabetic rats is in agreement with the results of others who reported on the beneficial effects of systemic EPO administration on wound healing of ischemic skin wounds (Buemi et al., 2004) , diabetic wounds , and burn wounds (Galeano et al., 2006) in mice. We found that topically applied EPO increased VEGF and HP levels. VEGF is an endogenous stimulator of angiogenesis, and the expression of VEGF and its receptors is upregulated during wound healing (Brown et al., 1992; Corral et al., 1999) . Angiogenesis increases the delivery of oxygen and other nutrients that are necessary for local collagen synthesis (Buemi et al., 2004) . Takahashi et al. (2000) have shown that EPO can stimulate the production of collagen by activating fibroblasts. On the basis of the results of our study, we suggest that topical EPO exerts its beneficial effects on wounds by inducing capillary formation, increasing VEGF and collagen synthesis, and inhibiting apoptosis. It is possible that EPO ) and high-dose (3,000 IU ml À1 ) erythropoietin (EPO)-containing creams were applied topically to the wounds of non-diabetic and diabetic rats every second day for 12 days. .05-significance of the differences between the pooled VEGF and HP levels of the vehicle-treated wounds in non-diabetic and diabetic rats, or the pooled VEGF and HP levels in low-dose and the high-dose EPO-treated wounds in diabetic rats. ) and high-dose (3,000 IU ml À1 ) erythropoietin (EPO)-containing creams.
In each bar (c) represents the value of Bax/Bcl-x L ratio in each group. *Po0.05, **Po0.001-significance of the difference between the two EPO-treated wounds and the vehicle-treated wounds of the diabetic rat. # Po0.05,
##
Po0.001-significance of the differences of the pooled data of each study parameter from the vehicle-treated wounds in non-diabetic and diabetic rats, or the pooled data of each study parameter from the low-dose and the high-dose EPO-treated wounds in diabetic rats.
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may also have an indirect action on wound healing. For example, EPO may influence blood coagulation and the immune system. Therefore, it is unclear whether the local EPO effects are mediated by either direct and/or indirect stimulation of its receptors on its cutaneous cellular targets. Therefore, further studies are needed to elucidate its exact mode of action in healing wounds in healthy and diabetic individuals and animals.
In conclusion, topical EPO treatment promotes wound repair in diabetic rats. To the best of our knowledge, the results of this study show the efficacy of topical EPO treatment on wound healing in diabetic animals. On the basis of these results, we believe that topical EPO is a therapeutically beneficial method to treat chronic diabetic wounds.
MATERIALS AND METHODS

Animals
All experimental procedures were reviewed and approved by the Technion Animal Care and Use Committee. A total of 38 adult male Sprague-Dawley rats (220-250 g; 8-weeks old) were purchased from Harlan (Jerusalem, Israel) and singly housed in cages in a room with an artificial 12-h light/dark cycle at a constant temperature range (24±2 1C) and relative humidity (55±10%). The rats were acclimated for 1 week before the study and had free access to standard laboratory chow and water. Diabetes was then induced in 30 rats by a single 60 mg kg À1 intraperitoneal injection of streptozotocin (Sigma Aldrich, St Louis, MO) (Junod et al., 1969) . At 10 days after the streptozotocin injection, the blood glucose level in a drop of tail blood from each streptozotocin-injected rat was measured using a glucometer (FreeStyle, Abbott Diabetes Care, Alameda, CA). Rats were considered diabetic when their blood glucose levels were higher than 300 mg per 100 ml. Eight apparently healthy rats were used as the vehicle-treated non-diabetic control group. The duration of the study period was 12 days. At the beginning and end of the study period, each rat was weighed, and a blood sample was collected for determining the red blood cell, leukocyte, and platelet count, and hemoglobin levels. In addition, EPO levels in plasma and homogenates of excised wound tissues of each rat were determined using a commercial enzyme-linked immunosorbent assay (Quantikine IVD Erythropoietin Kit, R&D Systems, MN), in accordance with the manufacturer's protocol.
Full-thickness skin wound preparation and the various treatments
Skin wounds were made in ketamine/xylazine-anesthetized nondiabetic and diabetic rats. For the diabetic rats, these skin wounds were made 10 days after streptozotocin administration, and the presence of hyperglycemia was confirmed. Once anesthetized, the dorsal skin on each side of the vertebral column of each rat was shaved, and then cleaned before creating two 9-cm 2 full-thickness skin wounds using an aseptic technique (Figure 1a) . The 30 diabetic rats were then divided randomly into three treatment groups: (1) rats with wounds that were treated with 1 ml of cream that did not contain EPO (vehicle-treated diabetic group); (2) rats with wounds that were treated with 1 ml cream that contained 600 IU ml À1 EPO (low-dose EPO-treated group); (3) rats with wounds that were treated with 1 ml cream that contained 3,000 IU ml À1 EPO (high-dose EPO-treated group). The wounds of the eight non-diabetic control rats were treated with a cream that did not contain EPO (vehicletreated non-diabetic group). The wounds were then covered with a dressing film to prevent the cream from being removed, and to protect the wound during self-grooming. Treatments and bandaging with the dressing film were repeated every 2 days for 12 days under ketamine/xylazine anesthesia. The creams were prepared by a pharmacist in accordance with the recommendations in the United States Pharmacopoeia. EPO-containing creams were prepared by mixing 600 IU or 3,000 IU EPO with 1 g of a powder that contained 0.20% methyl paraben and 9% laureth/isoparafin/polyacrylamide, and then dissolved in deionized water in a final volume of 1 ml. EPO was purchased as an injection (ARANESP, Amgen AG, Zug, Switzerland), and each injection contained 150 mg ml À1 or 18,000 IU EPO. We determined that the stability of EPO in the cream was 1 month at 4 1C. Postoperative analgesics and antibiotics were not administered because these drugs may influence the healing process and thereby confound the interpretation of the data.
Quantitative assessment of wound healing (wound closure)
The size of the open wound was determined every 2 days on days 2, 4, 6, 8, 10, and 12 when the wounds were treated with the cream, and the bandage was replaced. To this end, transparent paper was placed over each wound, and the shape of the wound was drawn on the paper. The transparent paper was then superimposed on 1-mm 2 graph paper to calculate the surface area of the wound. The percentage of wound closure was calculated using the following formulae:
% non-closed wound area ¼ Wound area on day X Wound area on day zero Â100 % wound closure on day X ¼ 100%-% non-closed wound area
After measuring the area of the wound on day 12, the rats were killed humanely with a ketamine/xylazine anesthetic overdose.
Assessment of MVD
The expression levels of CD31 antigen (PECAM-1) can be used to assess MVD in healing wounds (Li et al., 2005) . Full-skin thickness samples of wound tissue from all the dead animals were excised carefully from the wound using a scalpel to avoid damaging its healing edge, fixed immediately in 10% neutral-buffered formalin, and then embedded in paraffin. Determination of the expression levels of CD31 antigen was performed by incubating the 5-mm-thick sections of the paraffin-embedded specimens with a mAb against tissue CD31 (R&D Systems), and then counterstaining them with hematoxylin. MVD was determined in five regions of interest in each specimen in which the CD31 antibody signal was the most intense. The number of blood vessels was counted under a light microscope by two investigators (YU and ZK) who were blinded to the treatment of the rats.
Determination of the VEGF content in the wounds
Samples (100 mg) of freshly excised wound tissue from each dead rat were homogenized in phosphate-buffered saline that contained a complete protease inhibitor cocktail (Sigma Aldrich) using an HG-homogenizer (model HG-300; MRC, Holon, Israel). The homogenates were then centrifuged and the supernatant was filtered.
The VEGF content in the filtrate was determined using the Quantikine Rat VEGF immunoassay (R&D Systems), in accordance with the manufacturer's protocol. Absorbance was measured in a fluorescent microplate reader at 450 nm. The amount of VEGF was expressed as picograms per mg of wound tissue.
Determination of the HP content in the wounds
Hydroxyproline (HP) levels were used as an indirect indicator of the amount of collagen in the wound tissues. A 100-mg sample of freshly excised wound tissue from each dead rat was hydrolyzed in HCl, and then diluted with deionized water. A 2-ml aliquot of the diluted solution was mixed with chloramines-T solution before adding p-dimethylaminobenzaldehyde. Samples (150 ml) of each solution were then transferred to a microtiter plate, and the absorbance of each sample was measured in a fluorescent microplate reader at 557 nm.
Determination of the extent of apoptosis and apoptosis sensitivity in the wounds
Apoptotic cells become increasingly more prevalent as wounds heal (Danielsen and Maihle, 2002) , and the ratio between pro-apoptotic and anti-apoptotic members of the Bcl-2 family can be used as a measure of apoptotic sensitivity (Zhang and Xu, 2000; Aguirre et al., 2004) . The extent of apoptosis in all the wounds was assessed by the TUNEL assay, using a commercial kit (ApopTag Plus Fluorescein Kit, CHEMICON, Temecula, CA) in accordance with the manufacturer's protocol. All samples were processed using a FACS Calibur analyzer (Becton Dickinson, Franklin Lakes, NJ), and data were analyzed using the Macintosh CELLQuest software program (Becton Dickinson). The expression levels of Bax, a pro-apoptotic protein, and Bcl-x L were determined by western blotting. Briefly, the samples of the excised wound tissues were homogenized in phosphate-buffered saline that contained a complete protease inhibitor cocktail using an HG-homogenizer, followed by lysis in radioimmunoprecipitation assay buffer (R&D Systems). A 40-mg aliquot of each protein lysate was loaded onto SDS-PAGE and then transferred to nitrocellulose membranes. Membranes were then incubated with monoclonal antibodies against Bax (Clone YTH6A7) and Bcl-x L (Clone YTH2H12) (R&D Systems), before a second incubation with a horseradish peroxidase-conjugated IgG secondary antibody. The resultant bands were quantified using densitometry. Apoptotic sensitivity was determined by calculating the ratio between the mean expression levels of Bax and Bcl-x L in each sample, and the results are expressed in arbitrary units.
Statistical analysis of the data
Data for each study parameter from the vehicle-and EPO-treated wound tissues for each group were then pooled, and the results are presented as mean ± standard deviation. The data showed a normal distribution by the Kolmogorov-Smirnov test. Data from each group were statistically analyzed by one-way analysis of variance using a computerized statistical program (Prism version 5.0, GraphPad Software, La Jolla, CA). Differences were considered statistically significant when Pp0.05.
